Apogee Therapeutics (APGE) Change in Accured Expenses (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Change in Accured Expenses data on file, last reported at $4.7 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $4.7 million, up 77.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $957000.0 (down 91.04% YoY), and the FY2025 annual result was -$1.1 million, down 117.07% from the prior year.
• Change in Accured Expenses advanced to $4.7 million in Q1 2026 per APGE's latest filing, from -$6.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $10.9 million in Q3 2023 and troughed at -$6.4 million in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.8 million in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses sank 769.35% in 2024, then jumped 250.94% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $1.9 million in 2022, then sank by 34.28% to $1.2 million in 2023, then slumped by 414.77% to -$3.9 million in 2024, then plunged by 63.46% to -$6.4 million in 2025, then jumped by 172.81% to $4.7 million in 2026.
• Business Quant data shows APGE's Change in Accured Expenses at $4.7 million in Q1 2026, -$6.4 million in Q4 2025, and $7.7 million in Q3 2025.